Rapport Therapeutics, Inc. Noncash or Part Noncash Acquisition, Fixed Assets Acquired
Rapport Therapeutics, Inc. (RAPP) reported Noncash or Part Noncash Acquisition, Fixed Assets Acquired of $49.00 thousand for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-07.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1 · last filed 2026-05-07
- Rapport Therapeutics, Inc. noncash or part noncash acquisition, fixed assets acquired for the quarter ending 2026-03-31 was $49.00K.
- Rapport Therapeutics, Inc. noncash or part noncash acquisition, fixed assets acquired for the quarter ending 2025-12-31 was -$45.00K, a 129.03% decline year-over-year.
- Rapport Therapeutics, Inc. noncash or part noncash acquisition, fixed assets acquired for the quarter ending 2025-03-31 was $0.00, a 100.00% decline year-over-year.
- Rapport Therapeutics, Inc. noncash or part noncash acquisition, fixed assets acquired for the quarter ending 2024-12-31 was $155.00K.
- Rapport Therapeutics, Inc. noncash or part noncash acquisition, fixed assets acquired for fiscal 2025 was $20.00K, a 88.37% decline from fiscal 2024.
- Rapport Therapeutics, Inc. noncash or part noncash acquisition, fixed assets acquired for fiscal 2024 was $172.00K, a 39.84% increase from fiscal 2023.
- Rapport Therapeutics, Inc. noncash or part noncash acquisition, fixed assets acquired for fiscal 2023 was $123.00K.
| Period end | Noncash or Part Noncash Acquisition, Fixed Assets Acquired 3 month | Noncash or Part Noncash Acquisition, Fixed Assets Acquired 6 month | Noncash or Part Noncash Acquisition, Fixed Assets Acquired 9 month | Noncash or Part Noncash Acquisition, Fixed Assets Acquired 12 month |
|---|---|---|---|---|
| 2026-03-31 | $49.00K 10-Q · filed 2026-05-07 | $4.00K derived: sum of 2 quarters · filed 2026-05-07 | ||
| 2025-12-31 | -$45.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $20.00K 10-K · filed 2026-03-10 | ||
| 2025-09-30 | $65.00K 10-Q · filed 2025-11-06 | |||
| 2025-03-31 | $0.00 10-Q · filed 2026-05-07 | $155.00K derived: sum of 2 quarters · filed 2026-05-07 | ||
| 2024-12-31 | $155.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $172.00K 10-K · filed 2026-03-10 | ||
| 2024-09-30 | $17.00K 10-Q · filed 2025-11-06 | |||
| 2024-03-31 | $847.00K 10-Q · filed 2025-05-08 | $762.00K derived: sum of 2 quarters · filed 2025-05-08 | $882.00K derived: sum of 3 quarters · filed 2025-05-08 | |
| 2023-12-31 | -$85.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $35.00K derived: sum of 2 quarters · filed 2025-03-11 | $123.00K 10-K · filed 2025-03-11 | |
| 2023-09-30 | $120.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $208.00K 10-Q · filed 2024-11-07 | ||
| 2023-06-30 | $88.00K 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |